Adeline Durand
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Adeline Durand has a total of 120 co-authors. Here are the top co-authors by number of shared publications:
- Céline Vallot
Institut Curie
5 shared publications Ahmed Dahmani
Translational Research Department, Institut Curie, PSL University, Paris, France
2 shared publications- Elisabetta Marangoni
Translational Research Department, Institut Curie
2 shared publications - Grégoire Jouault
CNRS UMR3244, Institut Curie, PSL University, Paris, France
2 shared publications Justine Marsolier
CNRS UMR3244, Institut Curie, PSL University, Paris, France
2 shared publications- Leïla Perié
Institut Curie, Université PSL, Sorbonne Université, CNRS UMR168, Laboratoire Physico Chimie Curie, Paris, France
2 shared publications
Latest Publications
- Open Access
- 11 November 2026
- Published by Springer Nature in Nature
Epigenetic heterogeneity in breast tumours informs diagnosis and prognosis
Breast cancer, the most diagnosed cancer among women, is stratified by gene expression patterns into luminal and basal-like subtypes, and the latter is associated with worse prognosis1-3. Recent advances in single-cell technologies have underscored the presence of intratumour heterogeneity, which poses substantial challenges in cancer treatment and achieving long-term disease-free survival4-7. Here we extensively profile epigenetic heterogeneity in a cohort of treatment-naive human luminal tumours, which were obtained directly after surgical resection. By applying a single-cell epigenetic approach based on cytometry by time-of-flight, we identify a recurrent subpopulation of basal-like cells in luminal tumours with a conserved epigenetic signature across patients. These basal-like cells, also identified by deconvolution of whole-genome DNA methylation patterns, are characterized by high expression of aggressive oncogenic traits and downregulation of hormone receptor signalling. Direct comparison of single-cell proteomic and genomic profiling of monomethylation and trimethylation of histone 3 on lysine 4 revealed that these marks are key features associated with loss of luminal identity. Finally, we highlight the potential of concomitant single-molecule profiling of histone modifications on cell-free nucleosomes in blood as an epigenetic liquid biopsy approach for early diagnosis of breast cancer. Moreover, the epigenetic basal signature measured in blood is linked to prognosis, which enables the identification of patients at increased risk for disease relapse.
- 11 November 2026
- Published by Springer Nature in Nature
Open AccessEpigenetic heterogeneity in breast tumours informs diagnosis and prognosis
Breast cancer, the most diagnosed cancer among women, is stratified by gene expression patterns into luminal and basal-like subtypes, and the latter is associated with worse prognosis1-3. Recent advances in single-cell technologies have underscored the presence of intratumour heterogeneity, which poses substantial challenges in cancer treatment and achieving long-term disease-free survival4-7. Here we extensively profile epigenetic heterogeneity in a cohort of treatment-naive human luminal tumours, which were obtained directly after surgical resection. By applying a single-cell epigenetic approach based on cytometry by time-of-flight, we identify a recurrent subpopulation of basal-like cells in luminal tumours with a conserved epigenetic signature across patients. These basal-like cells, also identified by deconvolution of whole-genome DNA methylation patterns, are characterized by high expression of aggressive oncogenic traits and downregulation of hormone receptor signalling. Direct comparison of single-cell proteomic and genomic profiling of monomethylation and trimethylation of histone 3 on lysine 4 revealed that these marks are key features associated with loss of luminal identity. Finally, we highlight the potential of concomitant single-molecule profiling of histone modifications on cell-free nucleosomes in blood as an epigenetic liquid biopsy approach for early diagnosis of breast cancer. Moreover, the epigenetic basal signature measured in blood is linked to prognosis, which enables the identification of patients at increased risk for disease relapse.
- 19 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- p. OF1-OF18
H3K4me1-Mediated Epigenomic Priming of Chemoresistant Tumor States in Ovarian Cancer
Non-genetic intratumor heterogeneity underlies therapeutic failure in cancer, yet how resistant tumor states are encoded in patients remains unclear. In this study, we show that chemoresistant evolution in high-grade serous ovarian cancer (HGSOC) is prefigured by epigenetically primed tumor cell states present before therapy. Using multimodal single-nucleus approaches, we profile transcriptional programs and histone modifications from longitudinal frozen biopsies of 16 patients with HGSOC. Tumors comprise a limited set of functional states that evolve reproducibly under chemotherapy: proliferative and IFN-responsive states are depleted, whereas TNFα-associated and epithelial-mesenchymal transition–associated programs persist or expand. Chromatin profiling reveals that these resistant programs are broadly enriched for histone H3 lysine 4 monomethylation (H3K4me1) prior to treatment, indicating that features of resistance are epigenomically primed. Baseline tumor composition is associated with survival, and fibroblast remodeling accompanies malignant adaptation. Together, these findings identify epigenomic priming as a feature of chemoresistant tumor cell states and provide a scalable framework for anticipating resistance from biopsies. Significance: Using a clinically compatible multimodal single-nucleus approach, the authors show that chemoresistant evolution in HGSOC is prefigured by epigenetically primed tumor cell states present before therapy.
- 19 October 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- p. OF1-OF18
H3K4me1-Mediated Epigenomic Priming of Chemoresistant Tumor States in Ovarian Cancer
Non-genetic intratumor heterogeneity underlies therapeutic failure in cancer, yet how resistant tumor states are encoded in patients remains unclear. In this study, we show that chemoresistant evolution in high-grade serous ovarian cancer (HGSOC) is prefigured by epigenetically primed tumor cell states present before therapy. Using multimodal single-nucleus approaches, we profile transcriptional programs and histone modifications from longitudinal frozen biopsies of 16 patients with HGSOC. Tumors comprise a limited set of functional states that evolve reproducibly under chemotherapy: proliferative and IFN-responsive states are depleted, whereas TNFα-associated and epithelial-mesenchymal transition–associated programs persist or expand. Chromatin profiling reveals that these resistant programs are broadly enriched for histone H3 lysine 4 monomethylation (H3K4me1) prior to treatment, indicating that features of resistance are epigenomically primed. Baseline tumor composition is associated with survival, and fibroblast remodeling accompanies malignant adaptation. Together, these findings identify epigenomic priming as a feature of chemoresistant tumor cell states and provide a scalable framework for anticipating resistance from biopsies. Significance: Using a clinically compatible multimodal single-nucleus approach, the authors show that chemoresistant evolution in HGSOC is prefigured by epigenetically primed tumor cell states present before therapy.
- Top Cited Papers
- 11 April 2022
- Published by Springer Nature in Nature Genetics
- Vol. 54 (4) , 459-468
H3K27me3 conditions chemotolerance in triple-negative breast cancer
The persistence of cancer cells resistant to therapy remains a major clinical challenge. In triple-negative breast cancer, resistance to chemotherapy results in the highest recurrence risk among breast cancer subtypes. The drug-tolerant state seems largely defined by nongenetic features, but the underlying mechanisms are poorly understood. Here, by monitoring epigenomes, transcriptomes and lineages with single-cell resolution, we show that the repressive histone mark H3K27me3 (trimethylation of histone H3 at lysine 27) regulates cell fate at the onset of chemotherapy. We report that a persister expression program is primed with both H3K4me3 (trimethylation of histone H3 at lysine 4) and H3K27me3 in unchallenged cells, with H3K27me3 being the lock to its transcriptional activation. We further demonstrate that depleting H3K27me3 enhances the potential of cancer cells to tolerate chemotherapy. Conversely, preventing H3K27me3 demethylation simultaneously to chemotherapy inhibits the transition to a drug-tolerant state, and delays tumor recurrence in vivo. Our results highlight how chromatin landscapes shape the potential of cancer cells to respond to initial therapy.
- 11 April 2022
- Published by Springer Nature in Nature Genetics
- Vol. 54 (4) , 459-468
Top Cited PapersH3K27me3 conditions chemotolerance in triple-negative breast cancer
The persistence of cancer cells resistant to therapy remains a major clinical challenge. In triple-negative breast cancer, resistance to chemotherapy results in the highest recurrence risk among breast cancer subtypes. The drug-tolerant state seems largely defined by nongenetic features, but the underlying mechanisms are poorly understood. Here, by monitoring epigenomes, transcriptomes and lineages with single-cell resolution, we show that the repressive histone mark H3K27me3 (trimethylation of histone H3 at lysine 27) regulates cell fate at the onset of chemotherapy. We report that a persister expression program is primed with both H3K4me3 (trimethylation of histone H3 at lysine 4) and H3K27me3 in unchallenged cells, with H3K27me3 being the lock to its transcriptional activation. We further demonstrate that depleting H3K27me3 enhances the potential of cancer cells to tolerate chemotherapy. Conversely, preventing H3K27me3 demethylation simultaneously to chemotherapy inhibits the transition to a drug-tolerant state, and delays tumor recurrence in vivo. Our results highlight how chromatin landscapes shape the potential of cancer cells to respond to initial therapy.
- Top Cited Papers
- 31 May 2019
- Published by Springer Nature in Nature Genetics
- Vol. 51 (6) , 1060-1066
High-throughput single-cell ChIP-seq identifies heterogeneity of chromatin states in breast cancer
Modulation of chromatin structure via histone modification is a major epigenetic mechanism and regulator of gene expression. However, the contribution of chromatin features to tumor heterogeneity and evolution remains unknown. Here we describe a high-throughput droplet microfluidics platform to profile chromatin landscapes of thousands of cells at single-cell resolution. Using patient-derived xenograft models of acquired resistance to chemotherapy and targeted therapy in breast cancer, we found that a subset of cells within untreated drug-sensitive tumors share a common chromatin signature with resistant cells, undetectable using bulk approaches. These cells, and cells from the resistant tumors, have lost chromatin marks—H3K27me3, which is associated with stable transcriptional repression—for genes known to promote resistance to treatment. This single-cell chromatin immunoprecipitation followed by sequencing approach paves the way to study the role of chromatin heterogeneity, not just in cancer but in other diseases and healthy systems, notably during cellular differentiation and development.
- 31 May 2019
- Published by Springer Nature in Nature Genetics
- Vol. 51 (6) , 1060-1066
Top Cited PapersHigh-throughput single-cell ChIP-seq identifies heterogeneity of chromatin states in breast cancer
Modulation of chromatin structure via histone modification is a major epigenetic mechanism and regulator of gene expression. However, the contribution of chromatin features to tumor heterogeneity and evolution remains unknown. Here we describe a high-throughput droplet microfluidics platform to profile chromatin landscapes of thousands of cells at single-cell resolution. Using patient-derived xenograft models of acquired resistance to chemotherapy and targeted therapy in breast cancer, we found that a subset of cells within untreated drug-sensitive tumors share a common chromatin signature with resistant cells, undetectable using bulk approaches. These cells, and cells from the resistant tumors, have lost chromatin marks—H3K27me3, which is associated with stable transcriptional repression—for genes known to promote resistance to treatment. This single-cell chromatin immunoprecipitation followed by sequencing approach paves the way to study the role of chromatin heterogeneity, not just in cancer but in other diseases and healthy systems, notably during cellular differentiation and development.